Loading...
Market
What will be the next major regulatory action related to Illumina's acquisition of Grail by June 2025?
2
Resolution / Starting Odds
EU appeals ruling • 25%
Illumina submits new bid • 25%
No further action • 25%
Other • 25%
Official announcements from regulatory bodies, financial news outlets
Story
EU Top Court Rules in Favor of Illumina in $7.1 Billion Grail Deal Probe
Sep 3, 2024, 07:52 AM
The European Union's top court has ruled in favor of Illumina, a U.S. gene sequencing company, in its legal battle against EU antitrust regulators. The court determined that the EU overstepped its authority by investigating Illumina's $7.1 billion bid for Grail, a cancer diagnostic test maker. This ruling marks a significant victory for Illumina, which had previously abandoned the $7 billion bid due to regulatory scrutiny.
View original story
Similar markets
European Commission • 25%
U.S. Federal Trade Commission • 25%
China's State Administration for Market Regulation • 25%
Other • 25%
A cancer diagnostics company • 25%
A gene sequencing company • 25%
A biotech company unrelated to cancer diagnostics • 25%
No major acquisition • 25%
Illumina stock rises by more than 5% • 25%
Illumina stock rises by less than 5% • 25%
Illumina stock falls by less than 5% • 25%
Illumina stock falls by more than 5% • 25%
No major hurdles • 25%
Minor delays • 25%
Significant delays • 25%
Acquisition blocked • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved without conditions • 25%
Approved with conditions • 25%
Pending decision • 25%
Rejected • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
New Legislation Introduced • 25%
Existing Legislation Amended • 25%
No Action Taken • 25%
Other • 25%